Sees FY23 revenue $57.2B-$58.7B, consensus $58.07B.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MRK:
- Pharma Earnings: Q4 Hits and Misses in a Post-COVID-19 World
- Merck’s Keytruda approved by FDA for non-small cell lung cancer treatment
- Another Feather on Merck’s Cap: Keytruda’s NSCLC Treatment Gets Another Indication
- Merck Animal Health announces FDA approval for Bravecto Chews for Dogs
- Merck to stop Phase 3 KEYNOTE-991 trial